Researchers have made a breakthrough in the production of doxorubicin, a cancer drug, through metabolic engineering. The achievement appears to involve optimizing the biosynthesis of doxorubicin, possibly overcoming a long-standing bottleneck in the process. The details of the breakthrough are related to the structural analysis of a component called DoxA and the optimization of P450-redox partner interactions.